BACKGROUND: An expanded access program (EAP) provided patient access to
pemetrexed prior to its commercial availability. The current report consists of US patients in …

Background In a randomized phase III trial, pemetrexed plus cisplatin was associated with
improved survival compared with cisplatin alone for patients with malignant pleural …

Introduction Pemetrexed has established efficacy, and is the backbone for chemotherapy in
patients with malignant pleural mesothelioma (MPM). An International Expanded Access …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

Purpose This multicenter, phase III study compared overall survival (OS) of second-line
pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced …

Background CBP501, a synthetic duodecapeptide, increases cisplatin influx into tumor cells
through an interaction with calmodulin enhancing cisplatin cytotoxicity, and effects cell cycle …

Background Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the
treatment of malignant pleural mesothelioma (MPM). This Phase I/II study was conducted to …

8554 Background: Pemtrexed/cisplatin (PCisp) remains the standard frontline treatment for
advanced-stage MPM. However, a majority of patients are older and too fragile to tolerate …

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

Background The aim of this study was to evaluate the activity and toxicity of pemetrexed and
carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma …